Northwest Biotherapeutics (NWBO) Non-Current Assets (2010 - 2026)

Northwest Biotherapeutics' Non-Current Assets history runs 17 years deep, the most recent figure standing at $73.8 million for Q1 2026.

• In Q1 2026, Non-Current Assets rose 223.63% year-over-year to $73.8 million; the TTM figure through Mar 2026 stood at $73.8 million (up 223.63% YoY), while the FY2025 annual figure was $75.8 million, up 234.3% from the prior year.
• Non-Current Assets for Q1 2026 stood at $73.8 million, down from $75.8 million in the prior quarter.
• The five-year high for Non-Current Assets was $75.8 million in Q4 2025, with the low at $19.3 million in Q3 2022.
• The 5-year median for Non-Current Assets is $23.4 million (2023), against an average of $28.8 million.
• The sharpest annual moves came in 2022 and 2025: Non-Current Assets retreated 11.77% in 2022, then soared 234.3% in 2025.
• Northwest Biotherapeutics' Non-Current Assets stood at $21.9 million in 2022, then advanced by 8.41% to $23.7 million in 2023, then slipped by 4.52% to $22.7 million in 2024, then jumped by 234.3% to $75.8 million in 2025, then decreased by 2.54% to $73.8 million in 2026.
• Business Quant data shows NWBO's Non-Current Assets at $73.8 million in Q1 2026, $75.8 million in Q4 2025, and $23.4 million in Q3 2025.